Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM313 in Relapsed or Refractory Multiple Myeloma
NCT06126237Phase 2Not yet recruiting
- Sponsor
- Keymed Biosciences
- Start
- Feb 2024
- Primary completion
- Feb 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of cm313 in multiple myeloma (MM), sponsored by Keymed Biosciences. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
cm313
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06126237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126237.